Assessment of anti-streptokinase antibody in patients with heart diseases and normal subjects
IJI-Iranian Journal of Immunology. 2004; 1 (1): 63-70
in English
| IMEMR
| ID: emr-174286
ABSTRACT
Background:
Streptokinase, which is injected intravenously with a standard dose of 1.5 MIU, is the most widely used thrombolytic agent around the world. What is so important about this bioproduct is the level of anti-streptokinase [anti-sk] antibody in the population, which is directly correlated to the incidence of streptococcal infections in that population
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Language:
English
Journal:
Iran. J. Immunol.
Year:
2004
Similar
MEDLINE
...
LILACS
LIS